文献速递肺血管病与心包/心肌炎

临床恶化终点作为肺动脉高压死亡替代指标的系统评价与荟萃分析

Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · Circulation · 2022-07-08

该系统评价与荟萃分析纳入35个独立队列共9450例患者,评估肺动脉高压试验中临床恶化复合终点对死亡的替代性。PAH治疗显著减少临床恶化事件(RR 0.64,95%CI 0.55-0.73),但其对临床恶化的效应与对死亡的效应仅中度相关(R²trial 0.35,95%CI 0.10-0.59;P<0.0001)。临床恶化各组分在发生频率、治疗反应和患者重要性方面差异大,不可互换。

要点

  • PAH治疗显著降低临床恶化事件(RR 0.64,95%CI 0.55-0.73),但不能替代死亡终点。
  • 临床恶化与死亡的试验水平相关性仅中度(R²trial 0.35,95%CI 0.10-0.59)。
  • 临床恶化各组分频率与治疗反应差异大,住院和症状进展最常见。

核心结论

  • PAH治疗显著减少临床恶化事件,但试验水平的临床恶化不是死亡的替代终点。
  • 临床恶化各组分在频率、治疗反应和患者重要性上差异大,不可互换。

研究设计与样本

  • 纳入35个独立队列共9450例患者,评估PAH治疗对临床恶化的效应。
  • 通过回归分析评估临床恶化相对风险与死亡相对风险的决定系数。

主要发现

  • PAH治疗显著减少临床恶化事件(RR 0.64,95%CI 0.55-0.73)。
  • PAH相关住院RR 0.61(95%CI 0.47-0.79),治疗升级RR 0.57(95%CI 0.38-0.84),症状进展RR 0.58(95%CI 0.48-0.69)。
  • 纳入主要临床恶化定义事件后死亡的全体死亡率仅轻度降低(RR 0.860,95%CI 0.742-0.997)。
  • 临床恶化效应与死亡效应仅中度相关(R²trial 0.35,95%CI 0.10-0.59;P<0.0001)。

关键数值与推荐

  • 临床恶化定义事件权重比例:住院33.5%,症状进展32.3%,死亡6.7%,治疗升级5.6%,移植/房间隔造口术0.2%。
  • 临床恶化事件中49%为对患者主要重要,37%为轻至中度重要,14%为关键重要。

临床怎么用

  • PAH试验中临床恶化可作为复合终点,但解读治疗效应时需注意其不能替代死亡获益。
  • 临床恶化各组分不可互换,评估治疗时应关注各组分的频率和患者重要性差异。

局限性

  • 研究仅基于试验水平数据,未涵盖个体患者水平分析。
  • 临床恶化各组分定义和权重在纳入试验中可能存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical worsening (CW) is a composite end point commonly used in pulmonary arterial hypertension (PAH) trials. We aimed to assess the trial-level surrogacy of CW for mortality in PAH trials, and whether the various CW components were similar in terms of frequency of occurrence, treatment-related relative risk (RR) reduction, and importance to patients. METHODS: We searched MEDLINE, Embase, and the Cochrane Library (January 1990 to December 2020) for trials evaluating the effects of PAH therapies on CW. The coefficient of determination between the RR for CW and mortality was assessed by regression analysis. The frequency of occurrence, RR reduction, and importance to patients of the CW components were assessed. RESULTS: We included 35 independent cohorts (9450 patients). PAH therapies significantly reduced CW events (RR, 0.64 [95% CI, 0.55-0.73]), including PAH-related hospitalizations (RR, 0.61 [95% CI, 0.47-0.79]), treatment escalation (RR, 0.57 [95% CI, 0.38-0.84]) and symptomatic progression (RR, 0.58 [95% CI, 0.48-0.69]), and modestly reduced all-cause mortality when incorporating deaths occurring after a primary CW-defining event (RR, 0.860 [95% CI, 0.742-0.997]). However, the effects of PAH-specific therapies on CW only modestly correlated with their effects on mortality (R2trial, 0.35 [95% CI, 0.10-0.59]; P<0.0001), and the gradient in the treatment effect across component end points was large in the majority of trials. The weighted proportions of CW-defining events were hospitalization (33.5%) and symptomatic progression (32.3%), whereas death (6.7%), treatment escalation (5.6%), and transplantation/atrioseptostomy (0.2%) were infrequent. CW events were driven by the occurrence of events of major (49%) and mild-to-moderate (37%) importance to patients, with 14% of the events valued as critical. CONCLUSIONS: PAH therapies significantly reduced CW events, but study-level CW is not a surrogate for mortality in PAH trials. Moreover, components of CW largely vary in frequency, response to therapy, and importance to patients and are thus not interchangeable. REGISTRATION: URL: https://www.crd.york.ac.uk/PROSPERO; Unique identifier: CRD42020178949.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Tremblay É, Gosselin C, Mai V, et al. Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Circulation. 2022. PMID: 35862151. doi:10.1161/CIRCULATIONAHA.121.058635

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。